Author:
Porta Camillo,Nardone Valerio,Gray Steven G,Correale Pierpaolo,Mutti Luciano
Reference5 articles.
1. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial;Pinto;Lancet Oncol,2021
2. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma;Strizzi;J Pathol,2001
3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016
4. Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: analysis of cancer and leukemia group B and north central cancer treatment group (Alliance) trials;Wang;Oncologist,2017
5. Survival in good performance malignant pleural mesothelioma patients; prognostic factors and predictors of response;Rahouma;Asian Pac J Cancer Prev,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献